National Insulin Procurement is Implemented in Shandong Province, China
Chinese National Centralized Drug Procurement program is launched in 2019, aiming to lower drug prices and reduce drug expenditures by volume-based durg procurement.
According to《Notice on the Selection results of the Sixth Batch of National Centralized Drug Procurement (Insulin Special)》issued by Shandong Medical Security Bureau and Shangdong Provincial Health Commission, the centralized procurement of insulin will be officially carried out in the participated organizations in Shandong from May 26, 2022.
The selected products cover 16 varieties of second and third-generation insulin commonly used in clinical treatment, the price of which are cut by 48% on average with the maximum being 73%.
This batch of insulin will benefit approximately 1 million patients with diabetics in Shandong and is expected to save estimated CNY 700 million (USD 103.5 million) in costs each year.
This is also the first time that the national centralized drug procurement program has been implemented in biomedicines.
Selected reportsMore
Healthcare, Technology, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
EqualOcean Analysis
Read next
In-depth
In-depth
Technology
A Closer Look at China’s Cloud Service Market, Guessing Who Will Succeed? [1/2]
Jun 27, 2022 05:09 PM
In-depth
Healthcare
Exclusive Interview with Xu Qian, Managing Partner of Redhill Capital
Jun 27, 2022 12:24 PM
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.